The role of C-reactive protein as a prognostic marker in COVID-19

Authors: Dominic Stringer,1Philip Braude,2Phyo K Myint,3Louis Evans,4Jemima T Collins,5Alessia Verduri,6Terry J Quinn,7Arturo Vilches-Moraga,8Michael J Stechman,9Lyndsay Pearce,10Susan Moug,11Kathryn McCarthy,12Jonathan Hewitt,13 and Ben Carter1

Abstract

Background

C-reactive protein (CRP) is a non-specific acute phase reactant elevated in infection or inflammation. Higher levels indicate more severe infection and have been used as an indicator of COVID-19 disease severity. However, the evidence for CRP as a prognostic marker is yet to be determined. The aim of this study is to examine the CRP response in patients hospitalized with COVID-19 and to determine the utility of CRP on admission for predicting inpatient mortality.

Methods

Data were collected between 27 February and 10 June 2020, incorporating two cohorts: the COPE (COVID-19 in Older People) study of 1564 adult patients with a diagnosis of COVID-19 admitted to 11 hospital sites (test cohort) and a later validation cohort of 271 patients. Admission CRP was investigated, and finite mixture models were fit to assess the likely underlying distribution. Further, different prognostic thresholds of CRP were analyzed in a time-to-mortality Cox regression to determine a cut-off. Bootstrapping was used to compare model performance [Harrell’s C statistic and Akaike information criterion (AIC)].

Results

The test and validation cohort distribution of CRP was not affected by age, and mixture models indicated a bimodal distribution. A threshold cut-off of CRP ≥40 mg/L performed well to predict mortality (and performed similarly to treating CRP as a linear variable).

Conclusions

The distributional characteristics of CRP indicated an optimal cut-off of ≥40 mg/L was associated with mortality. This threshold may assist clinicians in using CRP as an early trigger for enhanced observation, treatment decisions and advanced care planning.

For More Information: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7989395/

Leave a Reply

Your email address will not be published.